CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
EnglishINTRODUCTION: Bleomycin-induced pneumonitis (BIP) is a scarcely manageable pulmonary toxicity that occurs in approximately 20% of patients who are affected with cancers that are treated with bleomycin-containing regimens. Generally, the clinical picture is extremely complicated and therapy is based on steroids. The overall response rate to such therapy is limited. Recent insights in BIP pathogenesis have indicated that a key feature is deregulated mechanisms of tissue repair that are driven by profibrotic cytokines. Here we describe a patient with life-threatening BIP who was completely cured with imatinib mesylate (IM) after steroids and all other therapies had failed
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? / Carnevale-Schianca F; Gallo S; Rota-Scalabrini D; Sangiolo D; Fizzotti M; Caravelli D; Capaldi A; Anselmetti G; Palesandro E; D'Ambrosio L; Coha V; Obert R; Aglietta M; Grignani G.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - Aug 20;29:24e(2011), pp. 691-693.
| Titolo: | Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? |
| Autori Riconosciuti: | |
| Autori: | Carnevale-Schianca F; Gallo S; Rota-Scalabrini D; Sangiolo D; Fizzotti M; Caravelli D; Capaldi A; Anselmetti G; Palesandro E; D'Ambrosio L; Coha V; Obert R; Aglietta M; Grignani G. |
| Data di pubblicazione: | 2011 |
| Abstract: | INTRODUCTION: Bleomycin-induced pneumonitis (BIP) is a scarcely manageable pulmonary toxicity that occurs in approximately 20% of patients who are affected with cancers that are treated with bleomycin-containing regimens. Generally, the clinical picture is extremely complicated and therapy is based on steroids. The overall response rate to such therapy is limited. Recent insights in BIP pathogenesis have indicated that a key feature is deregulated mechanisms of tissue repair that are driven by profibrotic cytokines. Here we describe a patient with life-threatening BIP who was completely cured with imatinib mesylate (IM) after steroids and all other therapies had failed |
| Volume: | Aug 20;29 |
| Fascicolo: | 24e |
| Pagina iniziale: | 691 |
| Pagina finale: | 693 |
| Digital Object Identifier (DOI): | 10.1200/JCO.2011.35.6733 |
| Parole Chiave: | Imatinib Mesylate; Bleomycin-induced pneumonitis; pulmonary toxicity |
| Rivista: | JOURNAL OF CLINICAL ONCOLOGY |
| Appare nelle tipologie: | 03A-Articolo su Rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| JCO 2011_Carneval Schianca F eta al.pdf | PDF EDITORIALE | Accesso riservato | Open Access Visualizza/Apri |
Copyright © 2021